About Blueprint Genetics
Blueprint Genetics is a company based in Espoo (Finland) founded in 2012 by Juha Koskenvuo, Samuel Myllykangas, and Tero Pekka Alastalo was acquired by Quest Diagnostics in January 2020. Blueprint Genetics has raised $19.86 million across 2 funding rounds from investors including Quest Diagnostics, Creathor Venture and MTIP. Blueprint Genetics offers products and services including Whole Exome Sequencing, Diagnostic Panels, Nucleus Platform, and Single Gene Tests. Blueprint Genetics operates in a competitive market with competitors including Invitae, Myriad Genetics, Genome Medical, Centogene and Fulgent Genetics, among others.
- Headquarter Espoo, Finland
- Founders Juha Koskenvuo, Samuel Myllykangas, Tero Pekka Alastalo
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Blueprint Genetics Oy
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$19.86 M (USD)
in 2 rounds
-
Latest Funding Round
$15.96 M (USD), Series B
Jul 11, 2017
-
Investors
Quest Diagnostics
& 4 more
-
Employee Count
Employee Count
-
Acquired by
Quest Diagnostics
(Jan 22, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Blueprint Genetics
Blueprint Genetics offers a comprehensive portfolio of products and services, including Whole Exome Sequencing, Diagnostic Panels, Nucleus Platform, and Single Gene Tests.
Comprehensive sequencing of protein-coding genes for diagnostic purposes
Targeted tests for specific medical conditions like cardiology
Online tool for clinicians to order and manage genetic tests
Analysis of individual genes for variant detection
People of Blueprint Genetics
Unlock access to complete
Funding Insights of Blueprint Genetics
Blueprint Genetics has successfully raised a total of $19.86M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $15.96 million completed in July 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $16.0M
-
First Round
First Round
(29 Aug 2014)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2017 | Amount | Series B - Blueprint Genetics | Valuation | Creathor Venture , MTIP | |
| Aug, 2014 | Amount | Series A - Blueprint Genetics | Valuation | Inventure |
|
Investors in Blueprint Genetics
Blueprint Genetics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Quest Diagnostics, Creathor Venture and MTIP.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Venture capital fund focused on digital health and digital medical device companies
|
Founded Year | Domain | Location | |
|
Pontos Group is engaged in long-term investment management.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Blueprint Genetics
Financial Statements - Blueprint Genetics
Blueprint Genetics Comparisons
Competitors of Blueprint Genetics
Blueprint Genetics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Invitae, Myriad Genetics, Genome Medical, Centogene and Fulgent Genetics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Home-based genetic tests for detecting diseases are provided to individuals.
|
|
| domain | founded_year | HQ Location |
Molecular diagnostics and personalized medicine for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Genomic testing services are provided clinically and directly to consumers.
|
|
| domain | founded_year | HQ Location |
Provider of biochemical/genetic tests to detect mutations and rare diseases
|
|
| domain | founded_year | HQ Location |
Provider of genetic testing services for carrier screening cardiovascular diseases, epilepsy and cancer
|
|
| domain | founded_year | HQ Location |
High-throughput gene sequencing platform is developed for clinical diagnostics.
|
Frequently Asked Questions about Blueprint Genetics
Blueprint Genetics was founded in 2012 and raised its 1st funding round 2 years after it was founded.
Blueprint Genetics is headquartered in Espoo, Finland.
Blueprint Genetics is a funded company, having raised a total of $19.86M across 2 funding rounds to date. The company's 1st funding round was a Series A of $3.9M, raised on Aug 29, 2014.
Blueprint Genetics was founded in 2012 in Espoo, Finland, as a provider in the genetic diagnostics sector. Comprehensive next-generation sequencing (NGS) services, including targeted panels, whole exome analysis, and copy number variation (CNV) detection, are offered for hereditary conditions. Coverage extends to over 2,000 genes, with applications in areas such as cardiovascular, neurological, metabolic, and hereditary cancer diagnostics. Clinical-grade interpretation and medical statements are included in the offerings.
Blueprint Genetics's top competitors include Fulgent Genetics, Centogene and Myriad Genetics.
Blueprint Genetics offers Whole Exome Sequencing, Diagnostic Panels, Nucleus Platform, and Single Gene Tests.
Blueprint Genetics has 5 investors. Key investors include Quest Diagnostics, Creathor Venture, MTIP, Pontos Group, and Inventure VC.